CONTENTS:
- Addressing substance misuse: a missed opportunity in suicide prevention [Editorial]. Kalk N.J., Kelleher M.J., Curtis V., Morley K.I., p. 387-388.
- Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting [Addiction debate]. Peacock A., Larance B., Bruno R., Pearson S.A., Buckley N.A., Farrell M., et al., p. 389-399.
- Evaluating dynamic impacts of abuse-deterrent prescription opioid formulations. Humphreys K., p. 400-401.
- Are abuse-deterrent opioid formulations all they are crushed up to be? Nelson L.S., p. 401-402.
- What are our aims, and why? Jauncey M., p. 402-404.
- Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations. Peacock A., Larance B., Bruno R., Pearson S.A., Buckley N.A., Farrell M., et al., p. 404-405.
- Comparison of nicotine exposure during pregnancy when smoking and abstinent with nicotine replacement therapy: systematic review and meta-analysis. Hickson C., Lewis S., Campbell K.A., Cooper S., Berlin I., Claire R., et al., p. 406-424.
- The social location of harm from others' drinking in 10 societies. Room R., Callinan S., Greenfield T.K., Rekve D., Waleewong O., Stanesby O., et al., p. 425-433.
- Commentary on Room et al. (2019): Correlates of alcohol's harm to others across nations. Kim K.K., p. 434-435.
- Alcohol consumption and diabetes risk in a Chinese population: a Mendelian randomization analysis. Peng M., Zhang J., Zeng T., Hu X., Min J., Tian S., et al., p. 436-449.
- The interactive effects of perceived peer drinking and personality profiles on adolescent drinking: a prospective cohort study. Pocuca N., Hides L., Quinn C.A., White M.J., Mewton L., Newton N.C., et al., p. 450-461.
- Estimating alcohol-attributable fractions for injuries based on data from emergency department and observational studies: a comparison of two methods. Ye Y., Shield K., Cherpitel C.J., Manthey J., Korcha R., Rehm J., p. 462-470.
- Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Jones C.M., McCance-Katz E.F., p. 471-482.
- Commentary on Jones & McCance-Katze (2019): Buprenorphine and the glass half full-why can't we prescribe more of it, and will nurse practitioners and physician assistants fulfill a chronic unmet need? Lee J.D., McNeely J., p. 483-484.
- Disentangling longitudinal relations between youth cannabis use, peer cannabis use, and conduct problems: developmental cascading links to cannabis use disorder. Defoe I.N., Khurana A., Betancourt L.M., Hurt H., Romer D., p. 485-493.
- Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study. Ovrehus A., Nielsen S., Hansen J.F., Holm D.K., Christensen P., p. 494-503.
- An analysis of issues in the classification and reporting of heroin-related deaths. Stam N.C., Gerostamoulos D., Pilgrim J.L., Smith K., Moran L., Parsons S., et al., p. 504-512.
- Commentary on Stam et al. (2019): Drugs, death and statistics. Darke S., p. 513-514.
- Progressive nicotine patch dosing prior to quitting smoking: feasibility, safety and effects during the pre-quit and post-quit periods. Przulj D., Wehbe L., McRobbie H., Hajek P., p. 515-522.
- Pricing of tobacco products during, and after, the introduction of standardized packaging: an observational study of retail price data from independent and convenience (small) retailers in the United Kingdom. Critchlow N., Stead M., Moodie C., Angus K., Eadie D., MacKintosh A.M., p. 523-533.
- Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys. Degenhardt L., Bharat C., Bruno R., Glantz M.D., Sampson N.A., Lago L., et al., p. 534-552.
- Commentary on Degenhardt et al. (2019): Harm to others matters in substance use disorders, and so does discordance between the diagnostic systems. Room R., Rehm J., p. 553-554.
- E. M. Jellinek's disease concept of alcoholism. Kelly J.F., p. 555-559.
- Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. Sweeney S., Ward Z., Platt L., Guinness L., Hickman M., Hope V., et al., p. 560-570.
- Monitoring emerging prescription-drug related harms: a comment on Cairns et al.. Arunogiri S., Crossin R., Scott D., Lubman D.I., p. 571-572.
- Monitoring emerging prescription-drug related harms: a comment on Cairns et al. - in reply. Cairns R., Schaffer A.L., Ryan N., Pearson S.A., Buckley N.A., p. 572-573.
- Extension for Community Healthcare Outcomes (ECHO) as a tool for continuing medical education on opioid use disorder and comorbidities. Agley J., Adams Z.W., Hulvershorn L.A., p. 573-574.
- Dying alone: the sad irrelevance of naloxone in the context of solitary opiate use. Wojcicki J.M., p. 574-575.